1. Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
- Author
-
Mazagatos C, Mendioroz J, Rumayor MB, Gallardo García V, Álvarez Río V, Cebollada Gracia AD, Batalla Rebollo N, Barranco Boada MI, Pérez-Martínez O, Lameiras Azevedo AS, López González-Coviella N, Castrillejo D, Fernández Ibáñez A, Giménez Duran J, Ramírez Córcoles C, Ramos Marín V, Larrauri A, and Monge S
- Subjects
- Humans, Spain epidemiology, Infant, Incidence, Female, Male, Respiratory Syncytial Virus, Human, Sentinel Surveillance, Infant, Newborn, Antibodies, Monoclonal, Humanized therapeutic use, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections drug therapy, Hospitalization statistics & numerical data, Antiviral Agents therapeutic use
- Abstract
Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards., Methods: Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23., Results: We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction., (© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF